Aeterna Zentaris to stop late-stage cancer drug trial, shares fall
(Reuters) - Canadian drugmaker Aeterna Zentaris Inc said it would discontinue a late-stage trial of a cancer drug after an independent data safety monitoring committee said the drug was unlikely to help increase patient survival. Shares of the company fell as much as 29 percent to C$1.89 on Monday on the Toronto Stock Exchange. The committee recommended that patient enrollment be stopped and the study discontinued for perifosine, the company said in a statement. ...
Source: news.yahoo.com
No comments:
Post a Comment